Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

American Journal of Medicine

Volumn 118, Issue 9, 2005, Pages 939-947

  Deedwania, Prakash C ^a   Fonseca, Vivian A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Diabetes; Glucose intolerance; Metabolic syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; INTESTINE ENZYME; METFORMIN; NATEGLINIDE; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TOLBUTAMIDE; TRIACYLGLYCEROL LIPASE; TROGLITAZONE; VALSARTAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; ENDOTHELIUM INJURY; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEALTH CARE; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE; LIVER TOXICITY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EXERCISE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE;

EID: 24744437967     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.05.018     Document Type: Review

References (100)

1. H. King, R.E. Aubert, W.H. Herman Global burden of diabetes, 1995-2025 prevalence, numerical estimates, and projections Diabetes Care 21 1998 1414 1431
2. J.P. Boyle, A.A. Honeycutt, K.M. Narayan Projection of diabetes burden through 2050 impact of changing demography and disease prevalence in the U.S Diabetes Care 24 2001 1936 1940
3. J. Stamler, O. Vaccaro, J.D. Neaton, D. Wentworth Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial Diabetes Care 16 1993 434 444
4. W.B. Kannel, D.L. McGee Diabetes and glucose tolerance as risk factors for cardiovascular disease The Framingham Study Diabetes Care 2 1979 120 126
5. L.E. Eberly, J.D. Cohen, R. Prineas, L. Yang Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality the Multiple Risk Factor Intervention Trial experience Diabetes Care 26 2003 848 854
6. S.P. Laing, A.J. Swerdlow, S.D. Slater Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes Diabetologia 46 2003 760 765
7. J.E. Manson, G.A. Colditz, M.J. Stampfer A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women Arch Intern Med 151 1991 1141 1147
8. K. Malmberg, S. Yusuf, H.C. Gerstein Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry Circulation 102 2000 1014 1019
9. D.M. Shindler, J.B. Kostis, S. Yusuf Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry Am J Cardiol 77 1996 1017 1020
10. I.M. Stratton, A.I. Adler, H.A. Neil Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) prospective observational study BMJ 321 2000 405 412
11. M. Wei, S.P. Gaskill, S.M. Haffner, M.P. Stern Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study Diabetes Care 21 1998 1167 1172
12. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
13. P. Gaede, P. Vedel, N. Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
14. S.E. Kahn The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes Diabetologia 46 2003 3 19
15. C. Weyer, C. Bogardus, D.M. Mott, R.E. Pratley The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus J Clin Invest 104 1999 787 794
16. C. Weyer, P.A. Tataranni, C. Bogardus, R.E. Pratley Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development Diabetes Care 24 2001 89 94
17. DECODE Study Group on behalf of the European Diabetes Epidemiology Group Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26 2003 688 696
18. E.B. Levitan, Y. Song, E.S. Ford, S. Liu Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies Arch Intern Med 164 2004 2147 2155
19. National Cholesterol Education Program Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
20. H.M. Lakka, D.E. Laaksonen, T.A. Lakka The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2002 2709 2716
21. N. Sattar, A. Gaw, O. Scherbakova Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study Circulation 108 2003 414 419
22. D.E. Laaksonen, H.M. Lakka, L.K. Niskanen Metabolic syndrome and development of diabetes mellitus application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study Am J Epidemiol 156 2002 1070 1077
23. T. Nishikawa, D. Edelstein, X.L. Du Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404 2000 787 790
24. X. Du, T. Matsumura, D. Edelstein Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells J Clin Invest 112 2003 1049 1057
25. A.M. Schmidt, O. Hori, J.X. Chen Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice a potential mechanism for the accelerated vasculopathy of diabetes J Clin Invest 96 1995 1395 1403
26. A.M. Schmidt, S.D. Yan, J.L. Wautier, D. Stern Activation of receptor for advanced glycation end products a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis Circ Res 84 1999 489 497
27. A.E. Caballero, S. Arora, R. Saouaf Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes Diabetes 48 1999 1856 1862
28. H. Kawano, T. Motoyama, O. Hirashima Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery J Am Coll Cardiol 34 1999 146 154
29. P. Theuma, V.A. Fonseca Novel cardiovascular risk factors and macrovascular and microvascular complications of diabetes Curr Drug Targets 4 2003 477 486
30. V. Fonseca, C. DeSouza, S. Asnani, I. Jialal Nontraditional risk factors for cardiovascular disease in diabetes Endocr Rev 25 2004 153 175
31. R. Ross Atherosclerosis-an inflammatory disease N Engl J Med 340 1999 115 126
32. M.B. Pepys, G.M. Hirschfield C-reactive protein a critical update J Clin Invest 111 2003 1805 1812
33. K.C. Tan, N.M. Wat, S.C. Tam C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance Diabetes Care 26 2003 2323 2328
34. A. Festa, R. D'Agostino Jr, G. Howard Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS) Circulation 102 2000 42 47
35. E.S. Ford Body mass index, diabetes, and C-reactive protein among U.S. adults Diabetes Care 22 1999 1971 1977
36. M.A. Mendall, P. Patel, L. Ballam C reactive protein and its relation to cardiovascular risk factors a population based cross sectional study BMJ 312 1996 1061 1065
37. K. Tamakoshi, H. Yatsuya, T. Kondo The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state Int J Obes 27 2003 443 449
38. P. Muntner, J. He, J. Chen Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome analysis of the Third National Health and Nutrition Examination Survey (NHANES III) Ann Epidemiol 14 2004 686 695
39. S. Liu, J.E. Manson, J.E. Buring Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women Am J Clin Nutr 75 2002 492 498
40. P.M. Ridker, N. Rifai, L. Rose Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
41. A.D. Pradhan, J.E. Manson, N. Rifai C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 286 2001 327 334
42. P.M. Ridker, R.J. Glynn, C.H. Hennekens C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction Circulation 97 1998 2007 2011
43. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus N Engl J Med 348 2003 2294 2303
44. J. Tuomilehto, J. Lindstrom, J.G. Eriksson Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 2001 1343 1350
45. K.-F. Eriksson, F. Lindgarde Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study Diabetologia 34 1991 891 898
46. K.-F. Eriksson, F. Lindgarde No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo preventive trial with diet and exercise Diabetologia 41 1998 1010 1016
47. X.-R. Pan, G.-W. Li, Y.-H. Hu Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance the Da Qing IGT and Diabetes Study Diabetes Care 20 1997 537 544
48. W.C. Knowler, E. Barrett-Connor, S.E. Fowler Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
49. Diabetes Prevention Program Research Group The Diabetes Prevention Program (DPP) description of lifestyle intervention Diabetes Care 25 2002 2165 2171
50. G. Sartor, B. Schersten, S. Carlstrom Ten-year follow-up of subjects with impaired glucose tolerance prevention of diabetes by tolbutamide and diet regulation Diabetes 29 1980 41 49
51. W.C. Knowler, G. Sartor, A. Melander, B. Schersten Glucose tolerance and mortality, including a substudy of tolbutamide treatment Diabetologia 40 1997 680 686
52. C.L. Meinert, G.L. Knatterud, T.E. Prout, C.R. Klimt A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes II. Mortality results Diabetes 19 1970 789 815
53. R.L. Engler, D.M. Yellon Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease time for reconsideration Circulation 94 1996 2297 2301
54. M.C. Riddle Editorial sulfonylureas differ in effects on ischemic preconditioning-is it time to retire glyburide? J Clin Endocrinol Metab 88 2003 528 530
55. Diabetes Prevention Program Research Group Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program Diabetes Care 26 2003 977 980
56. The Diabetes Prevention Program Research Group Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program Diabetes Care 28 2005 888 894
57. W.H. Herman, T.J. Hoerger, M. Brandle The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance Ann Intern Med 142 2005 323 332
58. J.-L. Chiasson, R.G. Josse, R. Gomis Acarbose for prevention of type 2 diabetes mellitus the STOP-NIDDM randomised trial Lancet 359 2002 2072 2077
59. T. Kaiser, P.T. Sawicki Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data Diabetologia 47 2004 575 580
60. T.A. Buchanan, A.H. Xiang, R.K. Peters Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women Diabetes 51 2002 2796 2803
61. S. Yusuf, H. Gerstein, B. Hoogwerf Ramipril and the development of diabetes JAMA 286 2001 1882 1885
62. L. Hansson, L.H. Lindholm, L. Niskanen Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension the Captopril Prevention Project (CAPPP) randomised trial Lancet 353 1999 611 616
63. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic JAMA 288 2002 2981 2997
64. B. Dahlof, R.B. Devereux, S.E. Kjeldsen Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol Lancet 359 2002 995 1003
65. M.A. Pfeffer, K. Swedberg, C.B. Granger Effects of candesartan on mortality and morbidity in patients with chronic heart failure the CHARM-Overall programme Lancet 362 2003 759 766
66. H. Lithell, L. Hansson, I. Skoog The Study on Cognition and Prognosis in the Elderly (SCOPE) principal results of a randomized double-blind intervention trial J Hypertens 21 2003 875 886
67. S. Julius, S.E. Kjeldsen, M. Weber Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine the VALUE randomised trial Lancet 363 2004 2022 2031
68. L.H. Lindholm, M. Persson, P. Alaupovic Metabolic outcome during 1 year in newly detected hypertensives results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) J Hypertens 21 2003 1563 1574
69. A.J. Scheen Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials Diabetes Metab 30 2004 487 496
70. T. Pollare, H. Lithell, C. Morlin Metabolic effects of diltiazem and atenolol results from a randomized, double-blind study with parallel groups J Hypertens 7 1989 551 559
71. T. Pollare, H. Lithell, I. Selinus, C. Berne Sensitivity to insulin during treatment with atenolol and metoprolol a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients BMJ 298 1989 1152 1157
72. T.W. Gress, F.J. Nieto, E. Shahar Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus N Engl J Med 342 2000 905 912
73. T. Pollare, H. Lithell, C. Berne A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension N Engl J Med 321 1989 868 873
74. Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
75. M.I. Wiggam, S.J. Hunter, A.B. Atkinson Captopril does not improve insulin action in essential hypertension a double-blind placebo-controlled study J Hypertens 16 1998 1651 1657
76. A. Moan, A. Hoieggen, I. Seljeflot The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity J Hypertens 14 1996 1093 1097
77. K. Higashiura, N. Ura, Y. Miyazaki, K. Shimamoto Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension J Hum Hypertens 13 1999 S71 S74
78. M. Kinoshita, Y. Nakaya, N. Harada Combination therapy of exercise and angiotensin-converting enzyme inhibitor markedly improves insulin sensitivities in hypertensive patients with insulin resistance Circ J 66 2002 655 658
79. A. Oksa, M. Gajdos, V. Fedelesova Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension J Cardiovasc Pharmacol 23 1994 79 86
80. G. Paolisso, A. Gambardella, M. Verza ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients J Hum Hypertens 6 1992 175 179
81. G. Paolisso, M.R. Tagliamonte, A. Gambardella Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients J Hum Hypertens 11 1997 307 312
82. C. Top, B.Y. Cingozbay, H. Terekeci The effects of valsartan on insulin sensitivity in patients with primary hypertension J Int Med Res 30 2002 15 20
83. S.I. McFarlane, A. Kumar, J.R. Sowers Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease Am J Cardiol 91 2003 30H 37H
84. V.J. Dzau Tissue angiotensin and pathobiology of vascular disease a unifying hypothesis Hypertension 37 2001 1047 1052
85. M. Hernandez-Presa, C. Bustos, M. Ortego Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis Circulation 95 1997 1532 1541
86. P. Dandona, V. Kumar, A. Aljada Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-κ B, in mononuclear cells of normal subjects evidence of an antiinflammatory action J Clin Endocrinol Metab 88 2003 4496 4501
87. S. Engeli, R. Negrel, A.M. Sharma Physiology and pathophysiology of the adipose tissue renin-angiotensin system Hypertension 35 2000 1270 1277
88. A.M. Sharma, J. Janke, K. Gorzelniak Angiotensin blockade prevents type 2 diabetes by formation of fat cells Hypertension 40 2002 609 611
89. J.S. Torgerson, J. Hauptman, M.N. Boldrin, L. Sjostrom XENical in the prevention of diabetes in obese subjects (XENDOS) study a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 27 2004 155 161
90. A. Xiang, R. Peters, S. Kjos Continued protection from diabetes during treatment of the TRIPOD cohort with pioglitazone Diabetes 52 2003 A675 (abstract)
91. H.C. Gerstein, S. Yusuf, R. Holman Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention the DREAM trial Diabetologia 47 2004 1519 1527
92. V.A. Fonseca, D.E. Kelley, M.A. Baron, A.H. Marcellari Nateglinide has less potential for hypoglycemia than glyburide in subjects with type 2 diabetes and mild fasting hyperglycemia Diabetes 51 suppl 2 2002 A470 (abstract)
93. J.B. Kalbag, Y.H. Walter, J.R. Nedelman, J.F. McLeod Mealtime glucose regulation with nateglinide in healthy volunteers comparison with repaglinide and placebo Diabetes Care 24 2001 73 77
94. C. Saloranta, K. Hershon, M. Ball Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia J Clin Endocrinol Metab 87 2002 4171 4176
95. P.A. Hollander, S.L. Schwartz, M.R. Gatlin Importance of early insulin secretion comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes Diabetes Care 24 2001 983 988
96. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 28 suppl 1 2005 S37 S42
97. American Diabetes Association Prevention or delay of type 2 diabetes Diabetes Care 27 suppl 1 2004 S47 S54
98. J.B. Buse, J.L. Freeman, S.V. Edelman Serum 1,5-anhydroglucitol (GlycoMark™) a short-term glycemic marker Diabetes Technol Ther 5 2003 355 363
99. T. Yamanouchi, T. Inoue, E. Ogata Post-load glucose measurements in oral glucose tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance Clinical Science (Lond) 101 2001 227 233
100. S. Tsukui, Y. Fukumura, I. Kobayashi Decreased serum 1,5-anhydroglucitol in nondiabetic subjects with a family history of NIDDM Diabetes Care 19 1996 940 944